1. Nirmatrelvir and Ritonavir Efficacy: The combination of nirmatrelvir and ritonavir has shown promise in reducing the risk of death or hospitalization due to COVID-19, especially in clinically extremely vulnerable (CEV) individuals.
2. Treatment Efficacy in Patients With COVID-19: The study evaluated the efficacy of the antiviral drug combination nirmatrelvir and ritonavir in reducing the risk of death or hospitalization due to COVID-19 in 4 CEV cohorts.
3. Effectiveness Varies with Vulnerability: Although nirmatrelvir and ritonavir were associated with a reduced risk of death or hospitalization in CEV patients, this association was not found in lower-risk individuals (unvaccinated patients aged ≥70 years) who did not show a statistically significant benefit from the treatment when comorbidities were considered.